Clinical Trials Browser

Terminated × INDUSTRY × duvelisib × Clear all

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

13 enrolled 10 charts 1 FDA

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02391545 2023-09-28

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Phase 1/2 Terminated

55 enrolled 13 charts

Lymphoma, Follicular

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01476657 2021-03-17

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Phase 1 Terminated

Other hematologic neoplasm

Hematologic Neoplasms

NCT04342117 2021-03-17

REAL

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell